201 related articles for article (PubMed ID: 34494665)
1. Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.
Krens SD; van Boxtel W; Uijen MJM; Jansman FGA; Desar IME; Mulder SF; van Herpen CML; van Erp NP
Int J Cancer; 2022 Jan; 150(2):308-316. PubMed ID: 34494665
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
Krens SD; van Erp NP; Groenland SL; Moes DJAR; Mulder SF; Desar IME; van der Hulle T; Steeghs N; van Herpen CML
BMC Cancer; 2022 Mar; 22(1):228. PubMed ID: 35236333
[TBL] [Abstract][Full Text] [Related]
3. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
[TBL] [Abstract][Full Text] [Related]
4. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer.
van Boxtel W; Uijen MJM; Krens SD; Dijkema T; Willems SM; Jonker MA; Pegge SAH; van Engen-van Grunsven ACH; van Herpen CML
Eur J Cancer; 2022 Jan; 161():128-137. PubMed ID: 34920917
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
6. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
Castellano D; Pablo Maroto J; Benzaghou F; Taguieva N; Nguyen L; Clary DO; Jonasch E
Cancer Treat Rev; 2020 Sep; 89():102062. PubMed ID: 32659623
[TBL] [Abstract][Full Text] [Related]
7. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
Schmidinger M; Danesi R
Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
[TBL] [Abstract][Full Text] [Related]
8. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program.
Prisciandaro M; Ratta R; Massari F; Fornarini G; Caponnetto S; Iacovelli R; De Giorgi U; Facchini G; Scagliarini S; Sabbatini R; Caserta C; Peverelli G; Mennitto A; Verzoni E; Procopio G
Am J Clin Oncol; 2019 Jan; 42(1):42-45. PubMed ID: 30204614
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials.
McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM
J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113
[TBL] [Abstract][Full Text] [Related]
11. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).
Chen RC; Choueiri TK; Feuilly M; Meng J; Lister J; Marteau F; Falchook AD; Morris MJ; George DJ; Feldman DR
Cancer; 2020 Dec; 126(24):5311-5318. PubMed ID: 33022096
[TBL] [Abstract][Full Text] [Related]
12. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
13. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
[TBL] [Abstract][Full Text] [Related]
14. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B; Xu-Vuilard A; Jouinot A; Puisset F; Combarel D; Huillard O; Le Louedec F; Thomas F; Teixeira M; Flippot R; Mourey L; Albiges L; Pudlarz T; Joly C; Tournigand C; Chauvin J; Puszkiel A; Chatelut E; Decleves X; Vidal M; Goldwasser F; Oudard S; Medioni J; Vano YA
Br J Cancer; 2024 Apr; 130(6):961-969. PubMed ID: 38272963
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
16. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.
Cerbone L; Combarel D; Geraud A; Auclin E; Foulon S; Alves Costa Silva C; Colomba E; Carril L; Derosa L; Flippot R; Mir O; Khoudour N; Blanchet B; Escudier B; Paci A; Albiges L
ESMO Open; 2021 Dec; 6(6):100312. PubMed ID: 34864351
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK; McGregor B; Suárez C; Tsao CK; Kelly W; Vaishampayan U; Pagliaro L; Maughan BL; Loriot Y; Castellano D; Srinivas S; McKay RR; Dreicer R; Hutson T; Dubey S; Werneke S; Panneerselvam A; Curran D; Scheffold C; Choueiri TK; Agarwal N
J Clin Oncol; 2021 Nov; 39(33):3725-3736. PubMed ID: 34491815
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
Hirsch L; Martinez Chanza N; Farah S; Xie W; Flippot R; Braun DA; Rathi N; Thouvenin J; Collier KA; Seront E; de Velasco G; Dzimitrowicz H; Beuselinck B; Xu W; Bowman IA; Lam ET; Abuqayas B; Bilen MA; Varkaris A; Zakharia Y; Harrison MR; Mortazavi A; Barthélémy P; Agarwal N; McKay RR; Brastianos PK; Krajewski KM; Albigès L; Harshman LC; Choueiri TK
JAMA Oncol; 2021 Dec; 7(12):1815-1823. PubMed ID: 34673916
[TBL] [Abstract][Full Text] [Related]
19. U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
Singh H; Brave M; Beaver JA; Cheng J; Tang S; Zahalka E; Palmby TR; Venugopal R; Song P; Liu Q; Liu C; Yu J; Chen XH; Wang X; Wang Y; Kluetz PG; Daniels SR; Papadopoulos EJ; Sridhara R; McKee AE; Ibrahim A; Kim G; Pazdur R
Clin Cancer Res; 2017 Jan; 23(2):330-335. PubMed ID: 27793960
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]